Economic Evaluation of the UK Liver Transplantation Programme
Brief summary Objectives: For all patient groups for whom liver transplantation is provided in the UK, to provide information on the actual costs incurred, the survival experience of patients and their quality of life. For selected patient groups where data are available, to assess the net benefits in terms of improved survival and improved quality of life, and to assess the net costs incurred.To assess the variation that exists in both costs and benefits within the UK liver transplant programme, and to investigate the factors associated with such variation.
Methods:Prospective data relating to resource-use/costs, quality of life and survival will be collected on NHS-funded liver transplant candidates formally assessed for transplantation. Quality of life will be assessed using two generic health status measurement instruments: the SF-36 and the EuroQol. Comparison will be made of quality of life before and after transplantation. Data on longer term quality of life will be obtained from a single survey of all patients in the retrospective sample using the same quality of life questionnaire. Assessment of the gain in survival will be undertaken for all patients listed with specific indications. The assessment of the costs of the transplant procedure will consider four distinct components: assessment, candidacy, transplantation and post-transplant. Assessment of the additional costs incurred as a result of providing a liver transplant will be made for patients with one of the following indications: PBC, PSC, alcoholic cirrhosis and FHF.
Main collaborators: Dr James Neuberger (Queen Elizabeth Hospital) Dr Alex Jimson (Addenbrooke's Hospital) Dr Stephen Pollard (St James's Hospital) Dr John O'Grady (King's College Hospital) Dr Andrew Burroughs (Royal Free Hospital) and Dr Michael Thick (Freeman Hospital)